Effects of tissue type plasminogen activator in embolic versus mechanical models of focal cerebral ischemia in rats.
Tissue type plasminogen activator (tPA) can be effective therapy for embolic stroke by restoring cerebral perfusion. However, a recent experimental study showed that tPA increased infarct size in a mouse model of transient focal ischemia, suggesting a possible adverse effect of tPA on ischemic tissue per se. In this report, the effects of tPA in two rat models of cerebral ischemia were compared. In experiment 1, rats were subjected to focal ischemia via injection of autologous clots into the middle cerebral artery territory. Two hours after clot injection, rats were treated with 10 mg/kg tPA or normal saline. Perfusion-sensitive computed tomography scanning showed that tPA restored cerebral perfusion in this thromboembolic model. Treatment with tPA significantly reduced ischemic lesion volumes measured at 24 hours by >60%. In experiment 2, three groups of rats were subjected to focal ischemia via a mechanical approach in which a silicon-coated filament was used intraluminally to occlude the origin of the middle cerebral artery. In two groups, the filament was withdrawn after 2 hours to allow for reperfusion, and then rats were randomly treated with 10 mg/kg tPA or normal saline. In the third group, rats were not treated and the filament was not withdrawn so that permanent focal ischemia was present. In this experiment, tPA did not significantly alter lesion volumes after 2 hours of transient focal ischemia. In contrast, permanent ischemia significantly increased lesion volumes by 55% compared with transient ischemia. These results indicate that in these rat models of focal cerebral ischemia, tPA did not have detectable negative effects. Other potentially negative effects of tPA may be dependent on choice of animal species and model systems.
Meng
W
W
Department of Neurology, Harvard Medical School and Massachusetts General Hospital, Boston 02129, USA.
Wang
X
X
Asahi
M
M
Kano
T
T
Asahi
K
K
Ackerman
R H
RH
Lo
E H
EH
D000818:Animals; D020212:Carotid Artery Injuries; D002342:Carotid Artery, External; D004195:Disease Models, Animal; D005343:Fibrinolytic Agents / Q000627:therapeutic use / Q000633:toxicity; D020766:Intracranial Embolism; D002546:Ischemic Attack, Transient / Q000188:drug therapy*; D008297:Male; D051379:Mice; D020768:Middle Cerebral Artery; D051381:Rats; D017207:Rats, Sprague-Dawley; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use* / Q000633:toxicity*
D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator